SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

Clevidipine-d_7

Item No. 31979

Formal Name: 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, 3-methyl 5-[(1-oxobutoxy-d_7)methyl] ester
Synonym: *rac*-Clevidipine-d_7
MF: $C_{21}H_{16}Cl_2D_7NO_6$
FW: 463.4
Chemical Purity: ≥98% (Clevidipine)
Deuterium Incorporation: ≥99% deuterated forms (d_1-d_7); ≤1% d_0
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Clevidipine-d_7 is intended for use as an internal standard for the quantification of clevidipine (Item No. 23025) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

Clevidipine-d_7 is supplied as a solid. A stock solution may be made by dissolving the clevidipine-d_7 in the solvent of choice, which should be purged with an inert gas. Clevidipine-d_7 is soluble in methanol and DMSO.

Description

Clevidipine is an inhibitor of L-type calcium channels (IC_{50}s = 7.1 and 78.8 nM at -40 and -80 mV, respectively, in isolated guinea pig cardiomyocytes).[1] It preferentially inhibits L-type calcium channels in isolated rat portal vein over rat left ventricle (IC_{50}s = 427 and 20,417 nM, respectively).[2] Clevidipine decreases mean arterial pressure in anesthetized normotensive or spontaneously hypertensive rats with ED_{30} values of 316 and 58 nmol/kg, respectively. Formulations containing clevidipine have been used in the treatment of hypertension.

References

1. Yi, X., Vivien, B., and Lynch, C., III Clevidipine blockade of L-type Ca^{2+} currents: Steady-state and kinetic electrophysiological studies in guinea pig ventricular myocytes. *J. Cardiovasc. Pharmacol.* **36(5)**, 592-600 (2000).
2. Norlander, M., Sjöquist, P.O., Ericsson, H., *et al.* Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. *Cardiovasc. Drugs Ther.* **22(3)**, 227-250 (2004).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM